NEW YORK, April 9 - Eisai, a Japanese health care and pharmaceutical company, has signed a multi-year subscription to Incyte Genomics' LifeSeq Gold human sequence and ZooSeq animal model databases, the company said Monday.
Researchers at Eisai, which is based in Tokyo, will have 24-hour online access to the databases and to information technology support, Incyte said in a statement.
"We recognize that genome-based research is an integral component in today's drug discovery and when we completed our analysis of the various genomic data product offerings, we became convinced that the collaboration with Incyte Genomics will greatly strengthen our genome-based research activities," said Aishin Shinoda, senior vice president of Eisai, in a statement.
Financial terms of the deal were not disclosed.
As a LifeSeq Gold subscriber, Eisai will access a database that integrates proprietary expressed tag sequence and full-length gene sequence, as well as cDNA clones of the genes in the database. ZooSeq is a similar database containing sequences from rat, mouse, dog, and monkey genomes.Incyte's other customers in Japan include Sumitomo Pharmaceuticals and Sankyo.